Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia.

Schreuder, A B; Overduin, R J; Peltenburg, N C; de Boer, L; Bodewes, F A J A; Derks, T G J.

Afiliación

Schreuder AB; Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.
Overduin RJ; Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.
Peltenburg NC; Department of Metabolic Diseases and internal medicine Erasmus Medical Center Rotterdam The Netherlands.
de Boer L; Department of Metabolic Diseases, Amalia Children's Hospital Radboud University Medical Center Nijmegen The Netherlands.
Bodewes FAJA; Department of Pediatric Hepatology and Gastroenterology, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.
Derks TGJ; Department of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.

JIMD Rep ; 65(4): 207-211, 2024 Jul.

Article en En | MEDLINE | ID: mdl-38974608

ABSTRACT

No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

Palabras clave

desgammacarboxy prothrombin; glycogen storage disease type I; hepatocellular adenoma; hepatocellular carcinoma; tumor markers